Takeda news

Osaka, Japan, October 23, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today that it has received the Good Design Award 2009[*1] from the Japan Industrial Design Promotion Organization for the blister card packaging for Benet® 17.5 mg tablets, which is indicated for the treatment of osteoporosis.

Osaka, Japan, October 20, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today its principal sponsorship of the inaugural Yokohama Women's Marathon, which will be held on Sunday, November 15, 2009.

Osaka, Japan, October 1, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, S.A.

Osaka and Tokyo, Japan, October 1, 2009 --- Takeda Pharmaceutical Company Limited (Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd.

CAMBRIDGE, Mass., SEPTEMBER 11, 2009 – Takeda Pharmaceutical Company Limited (TSE:4502) and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

Osaka, Japan, September 10, 2009 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced today that it has introduced Cisco TelePresence™, －an advanced videoconferencing system providing both high-resolution visuals and a high-quality audio environment. Cisco TelePresence™ was provided by Cisco Systems G.K.

DEERFIELD, Ill., and OSAKA, Japan, September 4, 2009 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME) a complete response letter from the U.S.